LETTER TO THE EDITOR |
Loïc Marpeau, MD
Department of Obstetrics and Gynecology
Rouen University Hospital
76000 Rouen, France
Jacques Bénichou, MD, PhD
Department of Biostatistics
Rouen University Hospital and INSERM U657
Institute for Biomedical Research
University of Rouen
76000 Rouen, France
for the PREMAG Trial Group
| The first 20% of the full text of this article appears below. |
To the Editor.—
Brain protection remains a challenge in infants who are born very preterm. Given its potential neuroprotective properties, magnesium sulfate (MgSO4) has been one of the rare pharmacologic interventions used in randomized trials.1,2 Our PREMAG Trial Collaborative Group found nonsignificantly decreased risks of short-term severe white matter injury, mortality before